Experimental studies indicate that alterations in these metabolites, together with NLRP3 inflammasome activation and atrial fibrosis, increase susceptibility to AF, while targeted interventions on the microbiota can reduce the risk and intensity of arrhythmia [5,71,72]. The gene discussed is NLRP3; the disease is atrial fibrillation.